Literature DB >> 8824283

Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity.

P Sartipy1, B Johansen, G Camejo, B Rosengren, G Bondjers, E Hurt-Camejo.   

Abstract

Phospholipase A2 acting on low density lipoproteins in the extracellular arterial intima may form proinflammatory lipid mediators. Human nonpancreatic secretory phospholipase A2 has three regions that may associate with sulfated glycosaminoglycans. The apoB-100 molecule in low density lipoproteins also has glycosaminoglycan binding regions that could mediate its retention in the arterial intima. Here we report that human nonpancreatic phospholipase A2 isolated from a transfected cell line binds to glycosaminoglycans secreted by cultured human arterial smooth muscle cells. A gel mobility shift assay showed that the affinity of phospholipase A2 for glycosaminoglycans from a heparan sulfate/chondroitin sulfate proteoglycan was higher than for chondroitin sulfate glycosaminoglycans from a larger versican-like proteoglycan. Affinity chromatography confirmed these results. All glycosaminoglycans tested, at concentrations up to 100 microM, increased the activity of phospholipase A2 toward phosphatidylcholine liposomes. Above this concentration, heparan sulfate and heparin inhibited the enzyme. Heparin and chondroitin 6-sulfate increased phospholipase A2 activity on low density lipoproteins up to 4-fold at 100 microM, whereas heparan sulfate had no effect. The results indicate that human nonpancreatic secretory phospholipase A2 interacts with proteoglycans via their glycosaminoglycan moiety and that the enzyme activity may be modulated by the association of the enzyme and its substrate to the sulfated polysaccharides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824283     DOI: 10.1074/jbc.271.42.26307

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

Review 2.  The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis.

Authors:  Philip L S M Gordts; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

Review 3.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

Review 4.  Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques.

Authors:  L J De Windt; R S Reneman; G J Van der Vusse; M Van Bilsen
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Human group II 14 kDa phospholipase A2 activates human platelets.

Authors:  J Polgár; R M Kramer; S L Um; J A Jakubowski; K J Clemetson
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

6.  Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.

Authors:  Boris B Boyanovsky; Preetha Shridas; Michael Simons; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

7.  Glycosaminoglycan-lipoprotein interaction.

Authors:  U Olsson; G Ostergren-Lundén; J Moses
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

Review 8.  Role of secretory phospholipases in atherogenesis.

Authors:  Ann-Cathrine Jönsson-Rylander; Sofia Lundin; Birgitta Rosengren; Camilla Pettersson; Eva Hurt-Camejo
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

9.  HDL remodeling during the acute phase response.

Authors:  Anisa Jahangiri; Maria C de Beer; Victoria Noffsinger; Lisa R Tannock; Chandrashekar Ramaiah; Nancy R Webb; Deneys R van der Westhuyzen; Frederick C de Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-13       Impact factor: 8.311

10.  Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves.

Authors:  Satu Lehti; Reijo Käkelä; Sohvi Hörkkö; Outi Kummu; Satu Helske-Suihko; Markku Kupari; Kalervo Werkkala; Petri T Kovanen; Katariina Oörni
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.